Alumis said it is pulling back from a would-be rival to Amgen’s Tepezza after assessing prospects for the asset it acquired. The company chose to punt the phase 3 path that had been envisaged prior to the deal, effectively reframing its development strategy. The move highlights how late-stage program economics and risk profiles can change quickly after acquisition—particularly in markets where pricing, competitive dynamics and label differentiation pressure returns on capital. The decision comes amid a broader pattern in biotech where companies reallocate resources to programs with clearer regulatory and commercial pathways.